Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
630.00    30.00 (5.00%)
Bid:
626.00
Ask:
634.00
Spread: 8.00 (1.278%)
Market Cap: £762.36m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Form 8.3 - Amendment

23 Jan 2026 16:59

RNS Number : 2321Q
Serum Life Sciences
23 January 2026
Β 

The Form 8.3 announcement released today at 16.36 under RNS No 2275Q, should have been issued under the Company name of Serum Life Sciences Ltd and not under the Company name of Sareum Holdings PLC.

Β 

The announcement text is unchanged and is reproduced in full below.

Β 

Β 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Full name of discloser:

Serum Life Sciences Ltd

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and

beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Oxford Biomedica plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

23 January 2026

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

Β 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Β 

Class of relevant security:

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

3,771,098

3.12

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

3,771,098

3.12

Β 

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other employee options)

Β 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

Β 

Β 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Β 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

Β 

The currency of all prices and other monetary amounts should be stated.

Β 

(a) Purchases and sales

Β 

Class of relevant security

Purchase/sale

Number of securities

Price per unit

Β 

(b) Cash-settled derivative transactions

Β 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a

long/short position

Number of reference securities

Price per unit

Β 

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Β 

Class of relevant security

Product description

e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which

option relates

Exercise price per unit

Type

e.g.

American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Β 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Β 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

Β 

Β 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii)Β  the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

(c) Attachments

Β 

Is a Supplemental Form 8 (Open Positions) attached?

No

Β 

Date of disclosure:

23 January 2026

Contact name:

Andrew Coll

Telephone number*:

0203 746 6137

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

Β 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
RETEAKFDASLKEFA
Date   Source Headline
28th May 20217:00 amEQSOxford Biomedica (OXB): Driving innovation in a thriving CGT industry
28th May 20217:00 amRNSBlock Listing Application
28th May 20217:00 amRNSResult of AGM
27th May 20217:00 amRNSBoard Change
25th May 20219:21 amRNSDirector/PDMR Shareholding
21st May 202112:46 pmRNSPDMR Dealing
20th May 202111:42 amRNSPDMR Dealings
18th May 20217:00 amRNSOxford Biomedica upgrades financial guidance
10th May 202110:54 amRNSHolding(s) in Company
4th May 202110:29 amRNSTotal Voting Rights
4th May 202110:27 amRNSHoldings in Company
27th Apr 20212:40 pmRNS2020 Annual report and Accounts & AGM Notification
26th Apr 202112:32 pmRNSHolding(s) in Company
15th Apr 20217:00 amRNSFull year results
6th Apr 20217:00 amRNSOXB signs Agreement with Boehringer Ingelheim
1st Apr 202111:04 amRNSTotal Voting Rights
30th Mar 202110:22 amRNSHolding(s) in Company
19th Mar 20217:01 amRNSUpdate on Sanofi Collaboration & License Agreement
15th Mar 202110:03 amRNSNotice of Preliminary Results
1st Mar 20219:36 amRNSTotal Voting Rights
26th Feb 202110:46 amRNSPDMR Dealings / Market Share sale
5th Feb 20211:22 pmRNSHoldings in Company
3rd Feb 20217:00 amRNSBoard Changes
1st Feb 20219:47 amRNSTotal Voting Rights
4th Jan 20212:09 pmRNSBlock Listing Return
4th Jan 20211:41 pmRNSTotal Voting Rights
30th Dec 20209:03 amRNSOXB notes AZ vaccine has been authorised in the UK
1st Dec 202012:17 pmRNSDirector Dealings
1st Dec 20209:02 amRNSTotal Voting Rights
23rd Nov 20208:47 amRNSOXB notes AZD1222 met primary efficacy endpoint
23rd Nov 20207:00 amRNSNon-Executive Director Appointment
9th Nov 20207:00 amRNSOXB and PhoreMost enter gene therapy collaboration
2nd Nov 20209:02 amRNSTotal Voting Rights
30th Oct 20207:00 amRNSAxovant update on AXO-Lenti-PD and virtual R&D day
23rd Oct 202010:27 amRNSDirector Purchase
12th Oct 20205:38 pmRNSHolding(s) in Company
6th Oct 202012:46 pmRNSAxovant update on 2nd cohort of SUNRISE-PD trial
6th Oct 20207:00 amRNSOXB receives approval for fourth suite in Oxbox
5th Oct 202010:59 amEQSEdison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution
2nd Oct 202011:52 amRNSTotal Voting Rights
29th Sep 20203:51 pmRNSDirector Dealings
24th Sep 20209:36 amRNSDirector/PDMR Shareholding
22nd Sep 202012:54 pmRNSDirector/PDMR Shareholding
17th Sep 20207:00 amRNSInterim Results
1st Sep 20209:33 amRNSTotal Voting Rights
1st Sep 20207:00 amRNSMaster Supply and Development Agreement with AZ
27th Aug 20207:00 amRNSNotice of Interim Results
25th Aug 20204:46 pmRNSBlock listing Application
3rd Aug 20209:41 amRNSTotal Voting Rights
3rd Aug 20207:00 amRNSOXB signs DMLA with Beam Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.